Psoriasiform dermatitis in a non-psoriatic patient treated with adalimumab

International Journal of Immunopathology and Pharmacology

Volumn 25, Issue 2, 2012, Pages 499-501

  Tammaro, A ^a   Persechino, S ^a   Abruzzese, Claudia ^a   Narcisi, A ^a   Cortesi, G ^a   Parisella, F R ^b   Lagana, B ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b TOWSON UNIVERSITY   (United States)

Author keywords

Adalimumab; Psoriasiformis dermatitis; Skin reactions; TNF alpha antagonist

Indexed keywords

ADALIMUMAB; AMINOTRANSFERASE; ETANERCEPT; IMMUNOGLOBULIN E;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HISTOLOGY; HUMAN; PAPILLOMATOSIS; PARAKERATOSIS; PRIORITY JOURNAL; PRURITUS; PSORIASIS; SKIN BIOPSY; SKIN DEFECT; SPONDYLARTHRITIS; UNDIFFERENTIATED SPONDYLARTHRITIS; HUMAN TISSUE; MIDDLE AGED; SIDE EFFECT; SKIN INFILTRATE; SKIN MANIFESTATION;

EID: 84863702349     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201202500220     Document Type: Article

References (13)

1. Tammaro A, Narcisi A, Di Russo PP, Abruzzese C, De Marco G, Persechino F, Parisella FR, Persechino S. Contact allergy to limonene from a home-made cosmetic. Eur J Inflamm (in press)
2. Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-a inhibitor induced psoriasis or psoriasiform exanthemata. First 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008; 9:1-14.
3. Gottlieb AB. Clinical research helps elucidate the role of tumor necrosis factor alpha (TNF-alpha) in the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenetic probes. Lupus 2003; 12(3):190-4. (Pubitemid 36458676)
4. Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003; 9(10):1245-50. (Pubitemid 37279838)
5. Müller-Ladner U, Alten R, Heiligenhaus A, et al. "TRECID", TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept. Dtsch Med Wochenschr 2009; 134:2132-6
6. Cassano N, Mastrandrea V, Principi M, Loconsole F, De Tullio N, Di Leo A, Vena GA. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. J Biol Regul Homeost Agents. 2011;25(2):285-9.
7. Bordignon V, Bultrini S, Prignano G, et al. High prevalence of latent tuberculosis infection in autoimmune disorders such as psoriasis and in chronic respiratory diseases, including lung cancer. J Biol Regul Homeost Agents 2011; 25(2):213-20.
8. Exarchou SA, Voulgari PV, Markatseli TE, Zioga A, Drosos AA. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol 2009; 38(5):328-31.
9. Kary S, Worm M, Audring H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor a antagonists. Ann Rheum Dis 2006; 65:405-7. (Pubitemid 43268235)
10. Takahashi H, Hashimoto Y, Ishida-Yamamoto A, Ashida T, Kohgo Y, Iizuka H. Psoriasiform and pustular eruption induced by infliximab. J Dermatol 2007; 34:446-72.
11. Lee HH, Song IH, Friedrich M, et al. Cutaneous side effects in patients with rheumatic diseases during application of tumor necrosis factor-a antagonists. Br J Dermatol 2007; 156:486-91
12. Kary S, Worm M, Audring H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor a antagonists. Ann Rheum Dis 2006; 65:405-7. (Pubitemid 43268235)
13. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002; 2:364-71. (Pubitemid 37328759)